Long-term Safety and Efficacy of Esketamine Nasal Spray Plus an Oral Antidepressant in Patients with Treatment-resistant Depression– an Asian Sub-group Analysis from the SUSTAIN-2 Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: To evaluate the long-term safety and efficacy of intranasal esketamine in patients with treatment-resistant depression from the Asian subgroup of the SUSTAIN-2 study. Methods: SUSTAIN-2 was a phase 3, open-label, single-arm, multicenter study comprising a 4-week screening, 4-week induction, 48-week optimization/maintenance, and 4-week follow-up (upon esketamine discontinuation) phase. Patients with treatment-resistant depression received esketamine plus an oral antidepressant during the treatment period. Results: The incidence of ≥ 1 serious treatment-emergent adverse event (TEAE) among the 78 subjects from the Asian subgroup (Taiwan: 33, Korea: 26, Malaysia: 19) was 11.5% (n = 9); with no fatal TEAE. 13 Asian patients (16.7%) discontinued esketamine due to TEAEs. The most common TEAEs were dizziness (37.2%), nausea (29.5%), dissociation (28.2%), and headache (21.8%). Most TEAEs were mild to moderate in severity, transient and resolved on the same day. Upon discontinuation of esketamine, no trend in withdrawal symptoms was observed to associate long-term use of esketamine with withdrawal syndrome. There were no reports of drug seeking, abuse, or overdose. Improvements in symptoms, functioning and quality of life, occurred during in the induction phase and were generally maintained through the optimization/maintenance phases of the study. Conclusion: The safety and efficacy of esketamine in the Asian subgroup was generally consistent with the total SUSTAIN-2 population. There was no new safety signal and no indication of a high potential for abuse with the long-term (up to one year) use of esketamine in the Asian subgroup. Most of the benefits of esketamine occurred early during the induction phase.
Abstract
Objective: To evaluate the long-term safety and efficacy of intranasal esketamine in patients with treatment-resistant depression from the Asian subgroup of the SUSTAIN-2 study. Methods: SUSTAIN-2 was a phase 3, open-label, single-arm, multicenter study comprising a 4-week screening, 4-week induction, 48-week optimization/maintenance, and 4-week follow-up (upon esketamine discontinuation) phase. Patients with treatment-resistant depression received esketamine plus an oral antidepressant during the treatment period. Results: The incidence of ≥ 1 serious treatment-emergent adverse event (TEAE) among the 78 subjects from the Asian subgroup (Taiwan: 33, Korea: 26, Malaysia: 19) was 11.5% (n = 9); with no fatal TEAE. 13 Asian patients (16.7%) discontinued esketamine due to TEAEs. The most common TEAEs were dizziness (37.2%), nausea (29.5%), dissociation (28.2%), and headache (21.8%). Most TEAEs were mild to moderate in severity, transient and resolved on the same day. Upon discontinuation of esketamine, no trend in withdrawal symptoms was observed to associate long-term use of esketamine with withdrawal syndrome. There were no reports of drug seeking, abuse, or overdose. Improvements in symptoms, functioning and quality of life, occurred during in the induction phase and were generally maintained through the optimization/maintenance phases of the study. Conclusion: The safety and efficacy of esketamine in the Asian subgroup was generally consistent with the total SUSTAIN-2 population. There was no new safety signal and no indication of a high potential for abuse with the long-term (up to one year) use of esketamine in the Asian subgroup. Most of the benefits of esketamine occurred early during the induction phase.
참고문헌 (62)
- Baldessarini RJ, "Morbidity in depressive disorders", Psychother Psychosom, 86, pp.65~72 (2017)
- MacQueen GM, "Cognitive dysfunction in major depression and bipolar disorder : assessment and treatment options", Psychiatry Clin Neurosci, 71, pp.18~27 (2017)
- Fava M, "Diagnosis and definition of treatment-resistant depression", Biol Psychiatry, 53, pp.649~659 (2003)
- Olfson M, "Prospective service use and health care costs of medicaid beneficiaries with treatment-resistant depression", J Manag Care Spec Pharm, 24, pp.226~236 (2018)
- Chien IC, "The prevalence and incidence of treated major depressive disorder among National Health Insurance enrollees in Taiwan, 1996 to 2003", Can J Psychiatry, 52, pp.28~36 (2007)
- Bromet E, "Cross-national epidemiology of DSM-IV major depressive episode", BMC Med, 9, pp.90~ (2011)
- Li CT, "Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder : cohort study", Br J Psychiatry, 200, pp.45~51 (2012)
- Jeng JS, "Repeated low-grade infections predict antidepressant-resistant depression : a nationwide population-based cohort study", J Clin Psychiatry, 79, pp.17~ (2018)
- Chan YE, "Treatment-resistant depression enhances risks of dementia and Alzheimer's disease : a nationwide longitudinal study", J Affect Disord, 274, pp.806~812 (2020)
- Kim N, "Epidemiology of pharmaceutically treated depression and treatment resistant depression in South Korea", PLoS One, 14, pp.e0221552~ (2019)
- Amos TB, "The humanistic and economic burden of treatment-resistant depression:a PHQ-9 severity analysis", the Anxiety and Depression Association of America (ADAA) Annual Conference (2017)
- Amos TB, "Direct and indirect cost burden and change of employment status in treatment-resistant depression : a matched-cohort study using a us commercial claims database", J Clin Psychiatry, 79, pp.17~ (2018)
- Li CT, "Major depressive disorder and stroke risks : a 9-year follow-up population-based, matched cohort study", PLoS One, 7, pp.e46818~ (2012)
- Kessler RC, "Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990-1992 to 2001-2003", JAMA, 293, pp.2487~2495 (2005)
- Soo-Jeong Kim, "Rapid Symptom Improvement in Major Depressive Disorder Using Accelerated Repetitive Transcranial Magnetic Stimulation", Clinical Psychopharmacology and Neuroscience, 19(1), pp.73~83 (2021), 대한정신약물학회[DOI]
- Reutfors J, "Mortality in treatment-resistant unipolar depression : a register-based cohort study in Sweden", J Affect Disord, 238, pp.674~679 (2018)
- DiBernardo A, "Humanistic outcomes in treatment resistant depression : a secondary analysis of the STAR*D study", BMC Psychiatry, 18, pp.352~ (2018)
- Olchanski N, "The economic burden of treatment-resistant depression", Clin Ther, 35, pp.512~522 (2013)
- "Highlights of prescribing information:SPRAVATO" (2020)[URL]
- "Spravato: EPAR - product information" (2019)[URL]
- Muller J, "Ketamine enantiomers in the rapid and sustained antidepressant effects", Ther Adv Psychopharmacol, 6, pp.185~192 (2016)
- Fedgchin M, "Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression : results of a randomized, double-blind, activecontrolled study(TRANSFORM-1)", Int J Neuropsychopharmacol, 22, pp.616~630 (2019)
- Popova V, "Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression : a randomized double-blind active-controlled study", Am J Psychiatry, 176, pp.428~438 (2019)
- Ochs-Ross R, "Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3", Am J Geriatr Psychiatry, 28, pp.121~141 (2020)
- Daly EJ, "Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression : a randomized clinical trial", JAMA Psychiatry, 76, pp.893~903 (2019)
- Kim J, "Esketamine for treatment-resistant depression-first FDA-approved antidepressant in a new class", N Engl J Med, 381, pp.1~4 (2019)
- "Highlights of prescribing information:KETALAR" (2020)[URL]
- Liang HJ, "Ketamine addiction", Dual Diagn Open Acc, 3, pp.37~ (2018)
- Feng LY, "Comparison of legislative management for new psychoactive substances control among Taiwan, South Korea, and Japan", Kaohsiung J Med Sci, 36, pp.135~142 (2020)
- Wajs E, "Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression : assessment of long-term safety in a phase 3, open-label study(SUSTAIN-2)", J Clin Psychiatry, 81, pp.19~ (2020)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders (DSM-5)" (2013), American Psychiatric Association
- Williams JB, "Development and reliability of a structured interview guide for the Montgomery Asberg depression rating scale(SIGMA)", Br J Psychiatry, 192, pp.52~58 (2008)
- Posner K, "Columbia classification algorithm of suicide assessment(C-CASA) : classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants", Am J Psychiatry, 164, pp.1035~1043 (2007)
- Bremner JD, "Measurement of dissociative states with the clinician-administered dissociative states scale(CADSS)", J Trauma Stress, 11, pp.125~136 (1998)
- Overall JE, "The brief psychiatric rating scale", Psychol Rep, 10, pp.799~812 (1962)
- Chernik DA, "Validity and reliability of the observer's assessment of alertness", sedation scale : study with intravenous midazolam, 1990, pp.10, 244~251
- Benedict RHB, "Hopkins verbal learning test – revised : normative data and analysis of inter-form and test-retest reliability", Clin Neuropsychol, 12, pp.43~55 (1998)
- Rickels K, "Physician withdrawal checklist(PWC-20)", J Clin Psychopharmacol, 28, pp.447~451 (2008)
- Humphrey L, "The bladder pain", interstitial cystitis symptom score : development, validation, and identification of a cut score, 2012, pp.61, 271~279
- Schweitzer I, "Sustained response to open-label venlafaxine in drug-resistant major depression", J Clin Psychopharmacol, 21, pp.185~189 (2001)
- Zimmerman M, "Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression", J Psychiatr Res, 38, pp.577~582 (2004)
- Spitzer RL, "Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient health questionnaire", JAMA, 282, pp.1737~1744 (1999)
- Spitzer RL, "A brief measure for assessing generalized anxiety disorder : the GAD-7", Arch Intern Med, 166, pp.1092~1097 (2006)
- Guy W, "ECDEU assessment manual for psychopharmacology", U.S. Department of Health, Education, and Welfare, ~ (1976)
- Sheehan DV, "The measurement of disability", Int Clin Psychopharmacol, 11(Suppl 3), pp.89~95 (1996)
- Herdman M, "Development and preliminary testing of the new five-level version of EQ-5D(EQ-5D-5L)", Qual Life Res, 20, pp.1727~1736 (2011)
- Janssen, "Position paper for the Taiwan Health Authority regarding the use of esketamine nasal spray in Taiwan", Asian patients, 2019
- Parker G, "Do the Chinese somatize depression? A cross-cultural study", Soc Psychiatry Psychiatr Epidemiol, 36, pp.287~293 (2001)
- Parker G, "Depression in the planet's largest ethnic group : the Chinese", Am J Psychiatry, 158, pp.857~864 (2001)
- Lee P, "Frequency of painful physical symptoms with major depressive disorder in Asia : relationship with disease severity and quality of life", J Clin Psychiatry, 70, pp.83~91 (2009)
- Novick D, "Which somatic symptoms are associated with an unfavorable course in Asian patients with major depressive disorder?", J Affect Disord, 149, pp.182~188 (2013)
- Gerhards SA, "The responsiveness of quality of life utilities to change in depression : a comparison of instruments(SF-6D, EQ-5D, and DFD)", Value Health, 14, pp.732~739 (2011)
- Walters SJ, "Comparison of the minimally important difference for two health state utility measures : EQ-5D and SF-6D", Qual Life Res, 14, pp.1523~1532 (2005)
- Pickard AS, "Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer", Health Qual Life Outcomes, 5, pp.70~ (2007)
- Kim K, "Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms", J Clin Pharmacol, 44, pp.1083~1105 (2004)
- Han C, "Do we need to consider ethno-cultural variation in the use of atypical antipsychotics for Asian patients with major depressive disorder?", CNS Drugs, 27(Suppl 1), pp.S47~S51 (2013)
- Bertilsson L, "Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s : clinical and interethnic aspects", Clin Pharmacol Ther, 82, pp.606~609 (2007)
- Dahl ML, "Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects", Pharmacogenetics, 5, pp.159~164 (1995)
- Johansson I, "Genetic analysis of the Chinese cytochrome P4502D locus : characterization of variant CYP2D6genes present in subjects with diminished capacity for debrisoquine hydroxylation", Mol Pharmacol, 46, pp.452~459 (1994)
- Chen ML, "Ethnic or racial differences revisited : impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics", Clin Pharmacokinet, 45, pp.957~964 (2006)
- Perez-Ruixo C, "Population pharmacokinetics of esketamine nasal spray and its metabolite noresketamine in healthy subjects and patients with treatment-resistant depression", Clin Pharmacokinet, 60, pp.501~516 (2021)
- Wang G, "Management of treatment-resistant depression in real-world clinical practice settings across Asia", Neuropsychiatr Dis Treat, 16, pp.2943~2959 (2020)